Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

BMC Infectious Diseases

Table 3 Eligibility for Short Course Regimen by Clinical Criteria and DST Performed. b. Participants with MDR-TB Eligible for Short Course Treatment Who Had Not Previously Received MDR-TB-Active Treatment, by DST Performed

Resistance Status	Xpert Only, N = 267	2nd-Line LPA Only,^a N = 217	Testing R, FQ, INJ, Z, and E, N = 210^b	Testing R, FQ, INJ, Z, E, Eto, and Cfz, N = 200^b
	# Eligible or Resistant / # Tested (%)^c	# Eligible or Resistant / # Tested (%)^c	# Eligible or Resistant / # Tested (%)^c	# Eligible or Resistant / # Tested (%)^c
Eligible for Short Course	267 / 267 (100)	67 / 217 (30.9)	11 / 210 (5.2)	10 / 200 (5.0)
Resistant to FQ or INJ	N/A	150 / 217 (69.1)	143 / 210 (68.1)	135 / 200 (67.5)
Resistant to Z or E	N/A	N/A	194 / 210 (92.4)	185 / 200 (92.5)
Resistant to FQ, INJ, Z, or E	N/A	N/A	199 / 210 (94.8)	189 / 200 (94.5)
Resistant to FQ, INJ, Z, E, Eto, or Cfz	N/A	N/A	N/A	190 / 200 (95.0)

^a2^nd-line LPA tests for susceptibility to isoniazid, rifampin, fluoroquinolones, and 2nd-line injectables (amikacin, capreomycin, or kanamycin)
^bR rifampin, FQ fluoroquinolone, INJ 2nd-line injectable, Z pyrazinamide, E ethambutol, Eto ethionamide, Cfz clofazimine
^cPercentages reported reflect number of participants with resistance or susceptibility divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows

ISSN: 1471-2334